UNSPSC 51322301: Cholestyramine or colestyramine

This classification denotes an anti-lipidemic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4B33BGI082. European Medicines Agency schedules Cholestyramine resin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01427MIG. Colestyramine generally arises in the molecular formula (C12H18CLN)N.(C10H10)N. The term 'colestyramine' is a Hazardous Substances Data Bank designation.

COLESTYRAMINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Cholestyramine or colestyramine bears US NLM identifiers UMLS ID C0008402 and NCI Concept Code C28929. SMILES: CCC1=CC=C(C=C1)C(C)CCC2=CC=C(C=C2)[N+](C)(C)C.[Cl-].

UNSPSC 51322301 Cholestyramine or colestyramine is a Commodity code that in practice encompasses a broader range of pharmaceutical procurement than the code name suggests. State and local health agencies and public safety departments source not only cholestyramine but generic and branded pharmaceuticals across multiple therapeutic classes — epinephrine, adenosine, diltiazem, labetalol, and similar agents — through formal bid and RFP processes. The issuing bodies include city purchasing departments procuring on behalf of fire rescue operations, state health and human services commissions managing pharmacy benefit programs, and multistate cooperative purchasing alliances distributing products across member jurisdictions. The scope of work ranges from direct supply of individual medication line items with firm pricing and expiration guarantees, to establishment of master pharmaceutical contracts with multiple authorized wholesalers and manufacturer-negotiated pricing models.

Recent activity spans Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department posted IFB 26P00188 for Advanced Life Support Medications for Tampa Fire Rescue with a due date of April 8, 2026 and estimated contract value of $40,000; the solicitation required sealed bids for four specific medication line items with firm pricing, nine-month minimum shelf life, and ten-day delivery, with a Small Local Business Enterprise bid discount available. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on vendors' capacity for direct contracting outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 in January 2026 with a March 26, 2026 due date for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local facilities, including Oregon; the contract term is two years with optional extensions, evaluation weighted 75 percent on price competitiveness, and awarded vendors must maintain relationships with at least two of three authorized wholesalers.